US Patent

US11911380 — Compositions and use of varenicline for treating dry eye

Method of Use · Assigned to Oyster Point Pharma Inc · Expires 2035-10-19 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and pharmaceutical formulations for treating dry eye disease using varenicline.

USPTO Abstract

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Drugs covered by this patent

varenicline-tartrate (VARENICLINE TARTRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1900`	—	varenicline-tartrate

Patent Metadata

Patent number: US11911380
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-19
Drug substance claim: No
Drug product claim: No
Assignee: Oyster Point Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.